The Evaluation of Prophylactic Efficacy of Newly Developed Reversible Inhibitors of Acetylcholinesterase in Soman-Poisoned Mice - A Comparison with Commonly Used Pyridostigmine

Basic and Clinical Pharmacology and Toxicology

Volumn 115, Issue 6, 2014, Pages 571-576

  Kassa, Jiri ^a   Korabecny, Jan ^a   Sepsova, Vendula ^a   Tumova, Martina ^a  

^a UNIVERSITY OF DEFENCE   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

1 (4 CARBAMOYLPYRIDINIO) 1' (2 HYDROXYIMINOMETHYLPYRIDINIO)DIMETHYL ETHER; 7 METHOXY N [2 [4 (3 METHYLBENZYL)PIPERAZINE 1 YL]ETHYL] 1,2,3,4 TETRAHYDROACRIDIN 9 AMINE TRIHYDROCHLORIDE; ATROPINE; CHOLINESTERASE INHIBITOR; N ETHYLTACRINE HYDROCHLORIDE; N HEXYL 7 METHOXYTACRINE HYDROCHLORIDE; N [2 [4 (3 BROMOBENZYL)PIPERAZINE 1 1 YL]ETHYL] 7 METHOXY 1,2,3,4 TETRAHYDROACRIDIN 9 AMINE TRIHYDROCHLORIDE; PYRIDOSTIGMINE; SOMAN; UNCLASSIFIED DRUG; 7-METHOXY-N-(2-(4-(3-METHYLBENZYL)PIPERAZINE-1-YL)ETHYL)-1,2,3,4-TETRAHYDROACRIDIN-9-AMINE; ANTIDOTE; N-(2-(4-(3-BROMOBENZYL)PIPERAZINE-1-YL)ETHYL)-7-METHOXY-1,2,3,4-TETRAHYDROACRIDIN-9-AMINE; N-ETHYLTACRINE; N-HEXYL-7-METHOXYTACRINE; PIPERAZINE DERIVATIVE; TACRINE;

ACUTE TOXICITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DEATH; DRUG EFFICACY; DRUG INTOXICATION; DRUG SCREENING; LD 50; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; COMPARATIVE STUDY; LD50;

MUS;

ANIMALS; ANTIDOTES; CHOLINESTERASE INHIBITORS; LETHAL DOSE 50; MALE; MICE; PIPERAZINES; PYRIDOSTIGMINE BROMIDE; SOMAN; TACRINE;

EID: 84925934689     PISSN: 17427835     EISSN: 17427843     Source Type: Journal    
DOI: 10.1111/bcpt.12269     Document Type: Article

References (40)

1. Colovic MB, Krstic DZ, Lazarevic-Pasti TD, Bondzic AM, Vasic VM. Acetylcholinesterase inhibitors: pharmacology and toxicology. Curr Neuropharmacol 2013;11:315-35.
2. Bajgar J. Organophosphate/nerve agent poisoning: mechanism of action, diagnosis, prophylaxis and treatment. Adv Clin Chem 2004;38:151-216.
3. Kassa J. Review of oximes in the antidotal treatment of poisoning by organophosphorus nerve agents. J Toxicol Clin Toxicol 2002;40:803-16.
4. Jokanovic M, Prostran M. Pyridinium oximes as cholinesterase reactivators. Structure-activity relationship and efficacy in the treatment of poisoning with organophosphorus compounds. Curr Med Chem 2009;16:2177-88.
5. Lugokenski TH, Gubert P, Bueno DC, Nogara PA, de Aquino Saraiva R, Barcelos RP et al. Effect of different oximes on rat and human cholinesterases inhibited by methamidophos: a comparative in vitro and in silico study. Basic Clin Pharmacol Toxicol 2012;111:362-70.
6. Zunec S, Kopjar N, Zeljezic D, Kuca K, Musilek K, Vrdoljak AL. In vivo evaluation of cholinesterase activity, oxidative stress markers, cyto- and genotoxicity of K048 oxime - a promising antidote against organophosphate poisoning. Basic Clin Pharmacol Toxicol 2014;114:344-51.
7. Shih TM. Comparison of several oximes on reactivation of soman-induced blood, brain and tissue cholinesterase activity in rats. Arch Toxicol 1993;67:637-46.
8. Lorke DE, Kalasz H, Petroianu GA, Tekes K. Entry of oximes into the brain: a review. Curr Med Chem 2008;15:743-53.
9. Zdarova Karasova J, Pohanka M, Musilek K, Zemek F, Kuca K. Passive diffusion of acetylcholinesterase oxime reactivators through the blood-brain barrier: influence of molecular structure. Toxicol In Vitro 2010;24:1838-44.
10. Layish I, Krivoy A, Rotman E, Finkelstein A, Tashma Z, Yehezkelli Y. Pharmacologic prophylaxis against nerve agent poisoning. Isr Med Assoc J 2005;7:182-7.
11. Bajgar J, Fusek J, Jun D, Kuca K, Bartosova L. Possibility of pharmacological prophylaxis against highly toxic organophosphates. Chem Listy 2007;101:81-3.
12. Bajgar J, Fusek J, Kassa J, Kuca K, Jun D. Chemical aspects of pharmacological prophylaxis against nerve agent poisoning. Curr Med Chem 2009;16:2977-86.
13. Wenger B, Quigley MD, Kokla MA. Seven-day pyridostigmine administration and thermoregulation during rest and exercise in dry heat. Aviat Space Environ Med 1993;64:905-11.
14. Kassa J, Vachek J. A comparison of the efficacy of pyridostigmine alone and the combination of pyridostigmine with anticholinergic drugs as pharmacological pretreatment of tabun-poisoned rats and mice. Toxicology 2002;177:179-85.
15. Marrs TC. Organophosphate poisoning. Pharmacol Ther 1993;58:51-66.
16. Kassa J, Koupilova M, Herink J, Vachek J. The long term influence of low-level sarin exposure on behavioral and neurophysiological functions in rat. Acta Medica (Hradec Kralove) 2001;44:21-7.
17. Korabecny J, Musilek K, Holas O, Binder J, Zemek F, Marek J et al. Synthesis and in vitro evaluation of N-alkyl-7-methoxytacrine hydrochloride as potential cholinesterase inhibitors in Alzheimer disease. Bioorg Med Chem Lett 2010;20:6093-5.
18. Tallarida R, Murray R. Manual of Pharmacological Calculation with Computer Programs. Springer-Verlag, New York, 1987.
19. Marrs TC, Rice P, Vale JA. The role of oximes in the treatment of nerve agent poisoning in civilian casualties. Toxicol Rev 2006;25:297-323.
20. Antonijevic B, Stojiljkovic MP. Unequal efficacy of pyridinium oximes in acute organophosphate poisoning. Clin Med Res 2007;5:71-82.
21. Bajgar J. Optimal choice of acetylcholinesterase reactivators for antidotal treatment of nerve agent intoxication. Acta Medica (Hradec Kralove) 2010;53:207-11.
22. Mercey G, Verdelet T, Renou J, Kliachyna M, Baati R, Nachon F et al. Reactivators of acetylcholinesterase inhibited by organophosphorus nerve agents. Acc Chem Res 2012;45:756-66.
23. Lorke DE, Hasan MY, Nurulain SM, Shafiullah M, Kuca K, Petroianu GA. Acetylcholinesterase inhibitors as pretreatment before acute exposure to organophosphates: assessment using methyl-paraoxon. CNS Neurol Disord Drug Targets 2012;11:1052-60.
24. Tuovinen K, Kaliste-Korhonen E, Raushel FM, Hanninen O. Success of pyridostigmine, physostigmine, eptastigmine and phosphotriesterase treatments in acute sarin intoxication. Toxicology 1999;134:169-78.
25. Maxwell DM, Brecht KM, Doctor BP, Wolfe AD. Comparison of antidote protection against soman by pyridostigmine, HI-6 and acetylcholinesterase. J Pharmacol Exp Ther 1993;264:1085-9.
26. Gordon RK, Haigh JR, Garcia GE, Feaster SR, Riel MA, Lenz DE. Oral administration of pyridostigmine bromide and huperzine A protects human whole blood cholinesterases from ex in vivo exposure to soman. Chem Biol Interact 2005;157:239-46.
27. Fusek J, Bajgar J, Merka V. Prophylaxe von Vergiftungen mit Nervenkampfstoffen (Ergebnisse einer klinischen Studie). Koord Sanitatsdienst 2006;24:48-53.
28. Dunn MA, Hackley BE, Sidell FR. Pretreatment for nerve agent exposure. In: Zajtchuk R, Bellamy RF, (eds). Textbook of Military Medicine: Medical Aspects of Chemical & Biological Warfare. Borden Institute, Walter Reed Army Medical Center, Washington, DC, 1997; 181-96.
29. Petroianu GA, Hasan MY, Nurulain SM, Arafat K, Sheen R, Nagelkerke N. Comparison of two pre-exposure treatment regimens in acute organophosphate (paraoxon) poisoning in rats: tiapride vs pyridostigmine. Toxicol Appl Pharmacol 2007;219:235-40.
30. Lorke DE, Hasan MY, Nurulain SM, Shafiullah M, Kuca K, Petroianu GA. Pretreatment for acute exposure to diisopropylfluorophosphate: in vivo efficacy of various acetylcholinesterase inhibitors. J Appl Toxicol 2011;31:515-23.
31. Kassa J, Musilek K, Koomlova M, Bajgar J. A comparison of the efficacy of newly developed reversible inhibitors of acetylcholinesterase with commonly used pyridostigmine as pharmacological pre-treatment of soman-poisoned mice. Basic Clin Pharmacol Toxicol 2012;110:322-6.
32. Petroianu GA, Nurulain SM, Shafiullah M, Hasan MY, Kuca K, Lorke DE. Usefulness of administration of non-organophosphate cholinesterase inhibitors before acute exposure to organophosphates: assessment using paraoxon. J Appl Toxicol 2013;33:894-900.
33. Komloova M, Musilek K, Horova A, Holas O, Dohnal V, Gunn Moore F et al. Preparation, in vitro screening and molecular modelling of symmetrical bis-quinolinium cholinesterase inhibitors-implications for early Myasthenia gravis treatment. Bioorg Med Chem Lett 2011;21:505-9.
34. Korabecny J, Musilek O, Holas O, Nepovimova E, Jun D, Zemek F et al. Synthesis and in vitro evaluation of N-(bromobut-3-en-7-yl)-7-methoxy-1, 2, 3, 4-tetrahydroacridin-9-amine as a cholinesterase inhibitor with regard to Alzheimer's disease treatment. Molecules 2010;15:8804-12.
35. Spilovska K, Korabecny J, Kral J, Horova A, Musilek K, Soukup O et al. 7-methoxy- tacrine-adamantylamine heterodimers as cholinesterase inhibitors in Alzheimer's disease treatment - synthesis, biological evaluation and molecular modeling studies. Molecules 2013;18:2397-418.
36. Masson P, Lockridge O. Butyrylcholinesterase for protection from organophosphorus poisons: catalytic complexities and hysteretic behavior. Arch Biochem Biophys 2010;494:107-20.
37. Rochu D, Chabriere E, Masson P. Human paraoxonase: a promising approach for pre-treatment and therapy of organophosphorus poisoning. Toxicology 2007;233:47-59.
38. Valiyaveettil M, Alamnech Y, Biggernann L, Soojhawon I, Doctor BP, Nambiar MP. Efficient hydrolysis of the chemical warfare agent tabun by recombinant and purified human and rabbit serum paraoxonase 1. Biochem Biophys Res Commun 2010;403:97-102.
39. Jun D, Musilova L, Kink M, Loiodice M, Nachon F, Roche D et al. Preparation and characterization of methoxy polyethylene glycol-conjugated phosphotriesterase as a potential catalytic bioscavenger against organophosphate poisoning. Chem Biol Interact 2010;187:380-3.
40. Saxena A, Doctor BP, Sun W, Luo C, Bansal R, Naik RS et al. HuBChE: a bioscavenger for protection against organophosphate chemical warfare agents. US Army Med Dep J 2004;7:22-9.